From a clinical perspective, these immunopathological mechanisms account for the variable presentations of adrenal insufficiency in patients receiving PD-1/PD-L1 therapy, ranging from subtle manifestations such as fatigue and hyponatraemia to life-threatening adrenal crisis. Here, PDCD1 is linked to acute adrenal insufficiency.